Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proof of cancer~* patient is considered for treatment with capecitabine or 5-FU~* hetero- or homozygous mutant for DPYD\*2A~* able and willing to give written informed consent~* able and willing to undergo blood sampling for pharmacokinetic analysis~* life expectancy 3 months or longer~* acceptable safety laboratory values (ANC, platelet count, ASAT, ALAT, creatinine,~* WHO performance status 0-2~* no radio- or chemotherapy within the last 3 weeks prior to study entry~Exclusion Criteria:~* patients with known alcoholism, drug addiction and/or psychotic disorders that are not suitable for adequate follow-up~* women who are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DPYD*2A (Type: EXPERIMENTAL): Patients are screened for a DPD-deficiency. Patients with a DPYD\*2A mutation are eligible for intervention with capecitabine/5-FU .

Based on this trial design, predict the completion outcome and termination type (if applicable).